Table 3.

Bispecific antibody studies

Drug	Target	No. of patients	Study design	Study phase	Results
Blinatumomab[71]	CD3/CD19	38	R/R FL, MCL, DLBCL	1	ORR/CR: 64%/38%; PFS 6.7 mo; OS 4.6 yr; OS ( for CR/PR): 7.7 yr; AEs: Infections (pneumonia, diarrhea, sepsis)
Mosunetuzumab[72]	CD3/CD20	218	R/R B-NHL	1	NHL ORR/CR: 64.1%/42.2%; DLBCL ORR/CR: 34.7%/16.6% AEs: CRS 28.4%, NAEs: 44%
CD20-TCB[73]	CD3/CD20	38	R/R DLBCL	1	ORR/CR: 47%/34% AEs: CRS 55.1%, Neutropenia 34.7%

AE: Adverse event; CR: Complete response; CRS: Cytokine releasing syndrome; DLBCL: Diffuse large B-Cell lymphoma; FL: Follicular lymphoma; MCL: Mantle cell lymphoma; NHL: Non-Hodgkin lymphoma; ORR: Objective response rate; OS: Overall survival; PFS: Progression-free survival; R/R: Relapsed/refractory.